Wednesday, August 20, 2014

Isotechnika officially changes name to Aurinia Pharma

Isotechnika officially changes name to Aurinia Pharma

October 22, 2013 by · Leave a Comment 

Tweet Isotechnika Pharma (TSX-V:ISA) has officially changed its name to Aurinia Pharmaceuticals and its common shares will be posted for trading on a 50:1 consolidated basis on the TSX Venture Exchange at the opening tomorrow under the trading symbol, AUP. The consolidation will result in 12,373,589 shares outstanding. “In many respects, the new Aurinia just […]

Isotechnika gets more funding for NICAM program

Isotechnika gets more funding for NICAM program

June 18, 2013 by · Leave a Comment 

Tweet Isotechnika Pharma (TSX: ISA) has received additional funding from the National Research Council Industrial Research Assistance Program (NRC-IRAP) for its non-immunosuppressive cyclophilin antagonist molecules (NICAM) program. NRC-IRAP continues to play an instrumental role in networking the NICAM program with key global partners and previously assisted Isotechnika in late-stage screening of several NICAM compounds, including […]

Glickman swinging for the fence again in Isotechnika merger

Glickman swinging for the fence again in Isotechnika merger

February 19, 2013 by · Leave a Comment 

Tweet Richard Glickman is poised to hit another home run with the proposed merger of his closely-held Aurinia Pharmaceuticals and Isotechnika Pharma (TSX:ISA) to create a global nephrology leader. Dr. Glickman has a decades-long track record of successfully developing and selling pharmaceutical and biopharmaceutical companies. For example, in 2001, he co-founded Aspreva Pharmaceuticals which went […]

ILJIN withdraws damage claims against Isotechnika

ILJIN withdraws damage claims against Isotechnika

January 15, 2013 by · Leave a Comment 

Tweet Isotechnika Pharma (TSX:ISA) announced that ILJIN Life Sciences of South Korea has formally notified Isotechnika and the arbitral tribunal that it has withdrawn all claims for damages in the parties’ pending arbitration arising from a development, distribution and license agreement. As previously reported, the agreement was declared to be in “full force and effect” […]

Isotechnika’s NICAMs effective against Hepatitis C virus

Isotechnika’s NICAMs effective against Hepatitis C virus

December 6, 2012 by · Leave a Comment 

Tweet Isotechnika Pharma (TSX:ISA) has announced positive anti-hepatitis C virus (HCV) results from the second round of in vitro testing of its cyclophilin antagonist molecules (NICAMs) carried out by the NIH’s National Institute of Allergy and Infectious Diseases. Several NICAM compounds were tested for cross genotype activity using quantitative polymerase chain reaction in HCV replicons, […]

Isotechnika receives partial award in ICC arbitration

Isotechnika receives partial award in ICC arbitration

November 30, 2012 by · Leave a Comment 

Tweet Isotechnika Pharma (TSX:ISA) has received a partial award from the International Chamber of Commerce Court of Arbitration regarding its right to terminate a development, distribution and license (DDL) agreement with ILJIN Life Sciences of South Korea. The partial award provides that the DDL has not been terminated and the company’s contractual relationship with ILJIN […]

FDA clears Isotechnika for Phase 3 voclosporin trial

FDA clears Isotechnika for Phase 3 voclosporin trial

November 26, 2012 by · Leave a Comment 

Tweet Isotechnika Pharma (TSX:ISA) has received permission from the FDA to commence the first of two planned Phase 3 kidney transplant trials for its lead product candidate, voclosporin, under a special protocol assessment (SPA) from the FDA. The SPA was received after the FDA reviewed Isotechnika’s Phase 2b data and evaluated the proposed Phase 3 […]

Isotechnika highlights upcoming milestones in Q3 report

Isotechnika highlights upcoming milestones in Q3 report

November 14, 2012 by · Leave a Comment 

Tweet Isotechnika Pharma (TSX:ISA) expects a decision shortly from the International Chamber of Commerce (ICC) Court of Arbitration on its right to terminate a development, distribution and license agreement with ILJIN Life Science Co. Isotechnika made the disclosure in its third quarter report. It terminated the accord with ILJIN last January. In addition, Isotechnika partner […]

Isotechnika’s NICAMs demonstrate anti-viral activity

Isotechnika’s NICAMs demonstrate anti-viral activity

November 6, 2012 by · Leave a Comment 

Tweet Isotechnika Pharma (TSX: ISA) announced positive results from the first round of screening of its portfolio of cyclophilin antagonist molecules (NICAMs) through the contract testing laboratories of the National Institute of Allergy and Infectious Disease, which is part of the NIH. NICAMs are an emerging novel class of multifunctional drugs showing promise as antiviral, […]

Isotechnika partner cleared for Phase 3 trial in China

Isotechnika partner cleared for Phase 3 trial in China

June 28, 2012 by · Leave a Comment 

Tweet Isotechnika Pharma (TSX:ISA) partner 3SBio (NASDAQ:SSRX) has received approval from the China’s State Food and Drug Administration to conduct a multi-center, Phase 3 clinical trial of voclosporin. According to the approved protocol, the randomized, multi-center, concentration-controlled and comparison study in kidney transplant patients is expected to begin enrolment in the third quarter of 2012. […]

Next Page »

Email Newsletters with Constant Contact
Google+